The ECS is one of the most prevalent systems in the body that represents untapped therapeutic potential in a wide range of disease areas. The ability to rapidly create new and improved drugs targeting the ECS, screen them for potential, and bring them to market is the focus of Indication Bio. Indication Bioscience will establish as a modern drug discovery platform that targets the ECS. The future of ECS medicine.
The ECS is a key neuromodultory system in the body that plays vital roles in the cellular processes that underpin many disease areas. The ECS controls and regulates many critical bodily functions. The ECS is currently understudied with many opportunities for development of novel therapies. Indication Bio is focused on modern approaches to medicine, efficient regulatory pathways to FDA approval, and the complex formularies of drug reimbursements by insurers. Modern drug production methods such as biosynthesis have been used for nearly a century to produce pharmaceutical ingredients and vitamins. The technology to produce small molecules targeting ECS receptors through biosynthesis already exists, and though this is a breakthrough, the real potential is in making future ECS molecules. Much of modern drug discovery is performed through biosynthesis. Modern drug discovery companies are successfully using biosynthesis to create and test new molecules for therapeutic potential. Modern drug discovery is creating tens of thousands of novel molecules each year, screening them for therapeutic potential, then licensing them to large pharmaceutical manufacturers. The value of applying a modern approach to the ECS is enormous.
Indication BioScience will begin by licensing the first of our Statin+ drug concepts, Atorva+. Based on traditional benchmarking methods, we expect initial payment sufficient to pay a significant dividend to investors, and to fund further development. The next major steps post-revenue will include further development of additional Statin+ drugs, an IPO to a major exchange, and the full build-out of the biosynthesis capability. The biosynthesis platform will not only discover next generation drugs, but also develop valuable production technology. Indication BioScience also expects through the course of work in biosynthesis to create proprietary technologies valuable in the production of API, and license these to manufacturers.
Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering pharmaceuticals, and are among the most widely prescribed class of drugs. Statins have been found to reduce cardiovascular disease and mortality in those who are at high risk, but also are associated with unwanted side effects. Indication BioScience has pioneered a new formulation platform for statins, Statin+ that increases effectiveness while decreasing side effects.
Copyright © 2018 Indication BioScience, LLC - All Rights Reserved.